GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » Gross Margin %

TOT Biopharm International Co (HKSE:01875) Gross Margin % : 72.40% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. TOT Biopharm International Co's Gross Profit for the six months ended in Jun. 2024 was HK$406 Mil. TOT Biopharm International Co's Revenue for the six months ended in Jun. 2024 was HK$560 Mil. Therefore, TOT Biopharm International Co's Gross Margin % for the quarter that ended in Jun. 2024 was 72.40%.

Warning Sign:

TOT Biopharm International Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -2.9%.


The historical rank and industry rank for TOT Biopharm International Co's Gross Margin % or its related term are showing as below:

HKSE:01875' s Gross Margin % Range Over the Past 10 Years
Min: 36   Med: 75.02   Max: 91.78
Current: 72.02


During the past 7 years, the highest Gross Margin % of TOT Biopharm International Co was 91.78%. The lowest was 36.00%. And the median was 75.02%.

HKSE:01875's Gross Margin % is ranked better than
65.42% of 749 companies
in the Biotechnology industry
Industry Median: 60.72 vs HKSE:01875: 72.02

TOT Biopharm International Co had a gross margin of 72.40% for the quarter that ended in Jun. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for TOT Biopharm International Co was -2.90% per year.


TOT Biopharm International Co Gross Margin % Historical Data

The historical data trend for TOT Biopharm International Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOT Biopharm International Co Gross Margin % Chart

TOT Biopharm International Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 75.02 69.05 36.00 83.82 73.53

TOT Biopharm International Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.10 81.52 76.21 71.59 72.40

Competitive Comparison of TOT Biopharm International Co's Gross Margin %

For the Biotechnology subindustry, TOT Biopharm International Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOT Biopharm International Co's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TOT Biopharm International Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where TOT Biopharm International Co's Gross Margin % falls into.



TOT Biopharm International Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

TOT Biopharm International Co's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=627.8 / 853.836
=(Revenue - Cost of Goods Sold) / Revenue
=(853.836 - 226.022) / 853.836
=73.53 %

TOT Biopharm International Co's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=405.8 / 560.452
=(Revenue - Cost of Goods Sold) / Revenue
=(560.452 - 154.694) / 560.452
=72.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


TOT Biopharm International Co  (HKSE:01875) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

TOT Biopharm International Co had a gross margin of 72.40% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


TOT Biopharm International Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TOT Biopharm International Co Business Description

Traded in Other Exchanges
N/A
Address
120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.
Executives
Center Laboratories, Inc. 2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited 2301 Trustee
Chengwei Evergreen Capital, Lp 2101 Beneficial owner
Center Laboratories Inc. 2101 Beneficial owner
Chengwei Evergreen Management, Llc 2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited 2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines